Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOSE A VAZQUEZ

Allopathic & Osteopathic Physicians Internal Medicine Infectious Disease

NPI
1518035054
CMS profile
294876
Location
AUGUSTA, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$41,116.62

105 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Allergan Inc. $30,470.41 86
Astellas Pharma US Inc $10,557.21 14
Gilead Sciences, Inc. $41.30 2
Merck Sharp & Dohme Corporation $27.93 2
Melinta Therapeutics, Inc. $19.77 1

Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOSE A VAZQUEZ

NPI 1518035054 · CMS profile ID 294876

Allopathic & Osteopathic Physicians / Internal Medicine / Infectious Disease

AUGUSTA, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1518035054?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOSE A VAZQUEZ, NPI 1518035054, CMS profile ID 294876. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1518035054?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JOSE A VAZQUEZ, NPI 1518035054, CMS profile ID 294876. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1518035054?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JOSE A VAZQUEZ, NPI 1518035054, CMS profile ID 294876, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1518035054?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

105 matching records · $41,116.62 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 105 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–105 of 105.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Allergan Inc. $1.0802/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671263037 CMS
Merck Sharp & Dohme Corporation $12.6802/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695250441 CMS
Allergan Inc. $0.8801/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671263023 CMS
Allergan Inc. $1.5801/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671263025 CMS
Allergan Inc. $0.9801/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671263029 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $41,116.62 105
PY2020 $17,683.80 63
PY2021 $15,236.52 59
PY2022 $27,029.38 97
PY2023 $75,634.59 151
PY2024 $57,621.21 135
PY2025 $100,913.65 127

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $32,564.50 20
PY2024 Principal investigator $52,266.60 40
PY2023 Principal investigator $123,686.06 13
PY2022 Recipient $6,400.00 2
PY2022 Principal investigator $25,625.00 5
PY2021 Principal investigator $166,144.93 32
PY2020 Principal investigator $193,655.09 33
PY2019 Principal investigator $38,152.00 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

20 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SCYNEXIS, Inc. $1,437.50 11/04/2025 Non-covered Recipient Entity
AUGUSTA UNIVERSITY RESEARCH INSTITUTE
A Phase 3, Multicenter, Prospective, Randomized, Double-blind Study of Two Treatment Regimens for Candidemia and/or Invasive Candidiasis: Intravenous Echinocandin followed by Oral Ibrexafungerp versus Intravenous Echinocandin followed by Oral Fluconazole No dispute reported 06/30/2026 1160765837
Principal investigator 1 Merck Sharp & Dohme LLC $11,516.00 10/20/2025 Non-covered Recipient Entity
Augusta Univ Research Institute Inc
A Test-Negative Case-Control Study to Evaluate the Effectiveness of V116 Against Pneumococcal Pneumonia in Older Adults No dispute reported 06/30/2026 1232940085
Principal investigator 1 SCYNEXIS, Inc. $1,772.50 08/28/2025 Non-covered Recipient Entity
AUGUSTA UNIVERSITY RESEARCH INSTITUTE
A Phase 3, Multicenter, Prospective, Randomized, Double-blind Study of Two Treatment Regimens for Candidemia and/or Invasive Candidiasis: Intravenous Echinocandin followed by Oral Ibrexafungerp versus Intravenous Echinocandin followed by Oral Fluconazole No dispute reported 06/30/2026 1160765851
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,875.00 07/23/2025 Non-covered Recipient Entity
Augusta University Research Inst. INC.
Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22) No dispute reported 06/30/2026 1248397521
Principal investigator 1 Dompe Farmaceutici S.p.A. $625.00 07/23/2025 Non-covered Recipient Entity
Augusta University Research Inst. INC.
Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22) No dispute reported 06/30/2026 1248397523
Principal investigator 1 Dompe Farmaceutici S.p.A. $130.80 07/07/2025 Non-covered Recipient Entity
Augusta University Research Inst. INC.
Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22) No dispute reported 06/30/2026 1248397525
Principal investigator 1 Dompe Farmaceutici S.p.A. $195.00 07/07/2025 Non-covered Recipient Entity
Augusta University Research Inst. INC.
Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22) No dispute reported 06/30/2026 1248397527
Principal investigator 1 Dompe Farmaceutici S.p.A. $130.80 07/07/2025 Non-covered Recipient Entity
Augusta University Research Inst. INC.
Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22) No dispute reported 06/30/2026 1248397529
Principal investigator 1 Dompe Farmaceutici S.p.A. $261.60 07/07/2025 Non-covered Recipient Entity
Augusta University Research Inst. INC.
Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22) No dispute reported 06/30/2026 1248397531
Principal investigator 1 Dompe Farmaceutici S.p.A. $2,013.40 07/07/2025 Non-covered Recipient Entity
Augusta University Research Inst. INC.
Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22) No dispute reported 06/30/2026 1248397533
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,875.00 06/18/2025 Non-covered Recipient Entity
Augusta University Research Inst. INC.
Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22) No dispute reported 06/30/2026 1248397517
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,875.00 06/18/2025 Non-covered Recipient Entity
Augusta University Research Inst. INC.
Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22) No dispute reported 06/30/2026 1248397519
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,177.20 04/25/2025 Non-covered Recipient Entity
Augusta University Research Inst. INC.
Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22) No dispute reported 06/30/2026 1248397505
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,177.20 04/25/2025 Non-covered Recipient Entity
Augusta University Research Inst. INC.
Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22) No dispute reported 06/30/2026 1248397507
Principal investigator 1 Dompe Farmaceutici S.p.A. $225.00 04/25/2025 Non-covered Recipient Entity
Augusta University Research Inst. INC.
Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22) No dispute reported 06/30/2026 1248397509
Principal investigator 1 Dompe Farmaceutici S.p.A. $40.00 04/25/2025 Non-covered Recipient Entity
Augusta University Research Inst. INC.
Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22) No dispute reported 06/30/2026 1248397511
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,250.00 04/25/2025 Non-covered Recipient Entity
Augusta University Research Inst. INC.
Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22) No dispute reported 06/30/2026 1248397513
Principal investigator 1 Dompe Farmaceutici S.p.A. $656.25 04/25/2025 Non-covered Recipient Entity
Augusta University Research Inst. INC.
Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22) No dispute reported 06/30/2026 1248397515
Principal investigator 1 SCYNEXIS, Inc. $2,687.50 04/24/2025 Non-covered Recipient Entity
AUGUSTA UNIVERSITY RESEARCH INSTITUTE
A Phase 3, Multicenter, Prospective, Randomized, Double-blind Study of Two Treatment Regimens for Candidemia and/or Invasive Candidiasis: Intravenous Echinocandin followed by Oral Ibrexafungerp versus Intravenous Echinocandin followed by Oral Fluconazole No dispute reported 06/30/2026 1160765783
Principal investigator 1 SCYNEXIS, Inc. $1,643.75 02/11/2025 Non-covered Recipient Entity
AUGUSTA UNIVERSITY RESEARCH INSTITUTE
A Phase 3, Multicenter, Prospective, Randomized, Double-blind Study of Two Treatment Regimens for Candidemia and/or Invasive Candidiasis: Intravenous Echinocandin followed by Oral Ibrexafungerp versus Intravenous Echinocandin followed by Oral Fluconazole No dispute reported 06/30/2026 1160765809